TY  - CHAP
M1  - Book, Section
TI  - Non–Small Cell Lung Cancer: General Principles, Management of Localized Disease, and Treatment of Metastatic Disease without Oncogene Drivers
A1  - Altan, Mehmet
A1  - Gulvin, Joshua M
A1  - Simon, George
A1  - Glisson, Bonnie
A2  - Kantarjian, Hagop M.
A2  - Wolff, Robert A.
A2  - Rieber, Alyssa G.
PY  - 2022
T2  - The MD Anderson Manual of Medical Oncology, 4e
AB  - KEY  CONCEPTSLung  cancer  is  the  leading  cause  of  cancer-related  death  in  the  United  States.  However,  patients  with  early  lung  cancer  have  lower  lung  cancer–related  mortality,  and  screening  with  low-dose  computed  tomography  in  high-risk  groups  correlates  with  a  reduction  in  overall  mortality.Multidisciplinary  evaluation,  including  early  integration  of  palliative  care,  for  patients  with  locally  advanced  or  metastatic  non–small  cell  lung  cancer  (NSCLC),  improves  patient  outcomes  and  quality  of  life.Immune  checkpoint  therapies,  particularly  therapies  targeting  the  programmed  cell  death  protein  1–programmed  cell  death  ligand  1  pathway  are  now  the  standard  (as  a  single  agent  or  as  a  part  of  combination)  therapy  for  first-line  treatment  of  metastatic  NSCLC  that  does  not  harbor  targetable  mutations  and  should  be  considered  for  all  patients  if  there  are  no  contraindications.  
SN  - 
PB  - McGraw Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1190834477
ER  -